Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambrosia Biosciences amylin agonist
- Development stage
- Unknown
- Lead developer
- Ambrosia Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ambrosia Biosciences is developing a small molecule amylin receptor agonist for the treatment of obesity and metabolic disorders. Currently in the discovery phase, the program is being designed for once-daily administration, either as a monotherapy or in combination with other metabolic therapies such as GLP-1 receptor agonists. The development process integrates cryo-EM-enabled structural biology, biophysical binding assays, and AI-powered molecular design. By targeting the amylin receptor as an agonist, the drug aims to mimic the physiological effects of amylin on satiety and glucose homeostasis, potentially offering an oral alternative to existing peptide-based injectable treatments.
- Other names
- Amylin receptor agonistAmbrosia amylin agonist
02
Targets
AMY receptor (Calcitonin receptor (with ramps))
Beyond the preview
Go deeper on Ambrosia Biosciences amylin agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambrosia Biosciences amylin agonist.